Top

Published in:

01-09-2010 | Brief Report

Beneficial effect of cinacalcet in a child with familial hypocalciuric hypercalcemia

Authors: Uri S. Alon, René G. VanDeVoorde

Published in: Pediatric Nephrology | Issue 9/2010

Abstract

We describe a child with familial hypocalciuric hypercalcemia (FHH) in whom the hypercalcemia seemed to interfere with tissue healing after tympanoplasty. Consequently, he was placed on cinacalcet (30 mg/day), changed after 2 weeks to 60 mg/day. The treatment resulted in a decrease in serum parathyroid hormone (PTH) from 148 to 32 pg/mL (normal 7–75) and ionized calcium from 1.48 to 1.23 mmol/L (1.13–1.34), as well as successful healing of the revised surgical scar. Over the 12-month treatment period no complications were noted. We conclude that cinacalcet may be considered a new, and currently the only, tool in treating children with symptomatic FHH.

Pollak MR, Brown EM, Chou YH, Herbert SC, Marx SJ, Steinmann B, Levi T, Seidman CE, Seidman JG (1993) Mutation in the human Ca²⁺-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell 75:1297–1303CrossRefPubMed

Pearce SHS, Trump D, Wooding C, Besser GM, Chew SL, Grant DB, Heath DA, Hughes IA, Paterson CR, Whyte MP, Thakker RV (1996) Calcium-sensing receptor mutations in familial hypocalciuric hypercalcaemia with recurrent pancreatitis. Clin Endocrinol 45:675–680CrossRef

Alon US (2007) Diseases and clinical applications of the calcium sensing receptor. Pediatr Endocrinol Rev 5:482–488PubMed

Brown EM, MacLeod RJ (2001) Extracellular calcium sensing and extracellular calcium signaling. Physiol Rev 81:239–297PubMed

Timmers HJ, Karperien M, Hamdy NA, de Boer H, Hermus AR (2006) Normalization of serum calcium by cinacalcet in a patient with hypercalcaemia due to a de novo inactivating mutation of the calcium-sensing receptor. J Intern Med 260:177–182CrossRefPubMed

Shoback DM, Bilezikian JP, Turner SA, McCary LC, Guo MD, Peacock M (2003) The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J Clin Endocrinol Metab 88:5644–5679CrossRefPubMed

Gal-Moscovici A, Sprague SM (2006) The role of calcimimetics in chronic kidney disease. Kidney Int Suppl 104:S68–S72CrossRef

Ritz E (2005) Calcimimetics—fooling the calcium receptor. Pediatr Nephrol 20:15–18CrossRefPubMed

Muscheites J, Wigger M, Drueckler E, Fischer DC, Kundt G, Haffner D (2008) Cinacalcet for secondary hyperparathyroidism in children with end-stage renal disease. Pediatr Nephrol 23:1823–1829CrossRefPubMed

10.

Silverstein DM, Kher KK, Moudgil A, Khurana M, Wilcox J, Moylan K (2008) Cinacalcet is efficacious in pediatric dialysis patients. Pediatr Nephrol 23:1817–1822CrossRefPubMed

11.

Platt C, Inward C, McGraw M, Dudley J, Tizard J, Burren C, Saleem MA (2010) Middle-term use of cinacalcet in paediatric dialysis patients. Pediatr Nephrol 25:143–148CrossRefPubMed

12.

Festen-Spanjer B, Haring CM, Koster JB, Mudde AH (2007) Correction of hypercalcaemia by cinacalcet in familial hypocalciuric hypercalcaemia. Clin Endocrinol 68:324–325

13.

Brown EM, Gamba G, Riccardi D, Lonbardi M, Butters R, Kifor O, Sun A, Hediger MA, Lytton J, Herbert SC (1993) Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature 366:575–580CrossRefPubMed

14.

Quarles LD (2003) Extracellular calcium-sensing receptors in the parathyroid gland, kidneys and other tissues. Curr Opin Nephrol Hypertens 12:349–355CrossRefPubMed

15.

Riccardi D, Hall AE, Chattopadhyay N, Xu JZ, Brown EM, Herbert SC (1998) Localization of the extracellular Ca+/polyvalent cation-sensing protein in rat kidney. Am J Physiol 274:F611–F622PubMed

16.

Nemeth EF, Steffey ME, Hammerland LG, Hung BC, Van Wagenen BC, Delmar EG, Balandrin MF (1998) Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA 95:4040–4045CrossRefPubMed

17.

Rus R, Haag C, Bumke-Vogt C, Bähr V, Mayr B, Möhlig M, Schulze E, Frank-Raue K, Raue F, Schöfl C (2008) Novel inactivating mutations of the calcium-sensing receptor: the calcimimetic NPS R-568 improves signal transduction of mutant receptors. J Clin Endocrinol Metab 93:4797–4803CrossRefPubMed

18.

Lu JYL, Yang Y, Gnacadja G, Christopoulos A, Reagan JD (2009) Effect of calcimimetic R-568 on correcting inactivating mutations in the human calcium-sensing receptor. J Pharm Exp Ther 331:775–786CrossRef

Title: Beneficial effect of cinacalcet in a child with familial hypocalciuric hypercalcemia
Authors: Uri S. Alon
René G. VanDeVoorde
Publication date: 01-09-2010
Publisher: Springer-Verlag
Published in: Pediatric Nephrology / Issue 9/2010
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI: https://doi.org/10.1007/s00467-010-1547-5

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Beneficial effect of cinacalcet in a child with familial hypocalciuric hypercalcemia

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2010

Letter to the editors regarding comments by Ghirardello et al. on the rasburicase article

Favorable outcome in a case of Mycoplasma pneumoniae-associated crescentic glomerulonephritis

Bleeding risk for surgical dialysis procedures in children with hemolytic uremic syndrome

The virtues of vitamin D—but how much is too much?

No juvenile arterial hypertension in sheep multiples despite reduced nephron numbers

Critical illness polyneuropathy after septic peritonitis in a boy with nephrotic syndrome